2026-08-21 / News

3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

2026-03-30 / News

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

2025-08-29 / News

3SBio Announces 2025 Interim Results: Value Realization of Innovative Achievements and Strong Long-Term Growth Momentum

2025-03-25 / News

3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong Value

2024-08-22 / News

3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase

2024-03-20 / News

3SBio reveals 2023 annual results: Revenue surges by 13.8% year on year, with pipelines to reap the rewards

3SBio will remain steadfast in its role as a national biopharmaceutical leader